15th week of 2011 patent applcation highlights part 31 |
Patent application number | Title | Published |
20110086798 | ERYTHROPOIETIN COMPOSITIONS - Methods and materials are provided for the production of compositions of erythropoietin protein, wherein said compositions comprise a pre-selected N-linked glycosylation pattern as the predominant N-glycoform. | 2011-04-14 |
20110086799 | GnRH II Analogs and Uses Thereof in the Immune System - Specially designed GnRH II analogs that are resistant to degradation by peptidases, are disclosed. The GnRH II analogs incorporate D-Arg, D-Leu, D-tBu-Ser, D-Trp, D-Asn or other active D amino acids at position 6 and aza-Gly-amide or other amino acid-amide at position 10. The D-Arg (6)—GnRH II-aza-Gly (10)-amide, D-Asn—GnRH II-aza-Gly (10)-amide, and D-Leu(6)—GnRH II-aza-Gly(10)-amide analogs are also provided, and demonstrate preferential binding to immune system GnRH receptors. These GnRH II analogs or their antibodies may be used in pharmaceutical preparations, and specifically in treatment of various immune system disorders. Antibodies to GnRH II, Applicant's GnRH TI analogs, and GnRH receptors can be used for the detection of GnRH II or the GnRH II analog or the GnRH II receptors as a diagnostic tool and/or to monitor treatment. | 2011-04-14 |
20110086800 | SCREENING METHOD FOR PREDICTING SUSCEPTIBILITY TO BREAST CANCER - A method to aid in identifying a familial or sporadic pattern of risk in at least one individual for developing cancer of a mucosal epithelial tissue, the method comprising screening said at least one individual for heterozygosity or homozygosity for a mutation in a gene coding for a Poly-Ig (Fc) receptor or a Poly-Ig-like (Fc) receptor capable of mediating inhibition of cancer cell growth by an immunoglobulin inhibitor. A method of treating an individual so identified includes enhancing the amount of immunoglobulin inhibitor contacting a mucosal epithelial tissue of said individual, and, especially in individuals homozygous for the defective receptor, may also include prophylactic surgery. Other methods include implementation of a risk reduction or prevention program in individuals identified as being at risk. | 2011-04-14 |
20110086801 | PREVENTION AND REDUCTION OF BLOOD LOSS - Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass. | 2011-04-14 |
20110086802 | METHODS TO INCREASE PERMEABILITY OF CORNEAL EPITHELIUM AND DESTABILIZE STROMAL COLLAGEN FIBRIL NETWORK - Methods of increasing the permeability of corneal epithelium to facilitate the diffusion of agents into the collagen fibrillar network of the stroma are provided. Used in combination, these methods open the epithelium to facilitate diffusion of stabilization molecules into the stroma and dissociate bridging molecules from stromal collagen fibers, thereby priming the collagen fibrillar network for restabilization by stabilization molecules. These methods can be used to increase the effectiveness and longevity of non-invasive corneal reshaping, such as orthokeratology, for correcting myopia, hyperopia and astigmatism. | 2011-04-14 |
20110086803 | PEPTIDES CONTAINING TRYPTOPHAN - The present invention relates to a process to produce a composition comprising water-soluble peptides and having a Trp/LNAA ratio of more than 0.15, which comprises hydrolyzing lysozyme, preferably hen eggs lysozyme, to prepare a hydrolysate having a DH of between 5 and 45. | 2011-04-14 |
20110086804 | TREATMENT OF PARKINSON'S DISEASE - Described herein are compositions and methods for the treatment of Parkinson's disease (PD) and/or to protect dopaminergic nigrostriatal neuronal cell bodies from 6-OHDA-induced neurotoxicity in a mammal. In various embodiments of the invention, the dopaminergic neuron differentiation factor sonic hedgehog (Shh) and/or its downstream transcription factor target Gli-1 are used in connection with gene therapeutic techniques or direct peptide injection for the aforementioned indications. Kits useful in practicing the inventive method are also disclosed, as are animal models useful for studying various neurodegenerative conditions. | 2011-04-14 |
20110086805 | IN VITRO METHOD FOR DIAGNOSING SKIN CANCER - The present invention relates to an in vitro method for identifying an individual suffering from or having a predisposition to skin cancer, characterized in that it comprises the step of analysing a biological sample originating from said individual by a) detecting a polymorphism of the MATP/SLC45A2 gene (SEQ ID NO: 1), and/or analysing the expression of the MATP/SLC45A2 gene; to the use, for preparing a composition for the treatment and/or prevention of a skin cancer in an individual, of a compound which specifically increases the expression of the MATP/SLC45A2 gene in a skin cell; and to a method for the selection, in vitro, of a compound capable of being of use in the treatment of skin cancer. | 2011-04-14 |
20110086806 | Polypeptides that Bind IL-23R - Polypeptides that bind to IL-23R including polypeptides having a multimerizing, e.g. trimerizing, domain and a polypeptide sequence that binds IL-23R. The multimerizing domain may be derived from human tetranectin. IL-23R binding polypeptides inhibit activation of IL-23R by native IL-23 and can be used as therapeutics agents for a variety of immune related disorders and cancers. Methods for selecting polypeptides and preparing multimeric complexes are described. | 2011-04-14 |
20110086807 | FIBROMODULIN FORMULATION FOR REDUCING CORNEAL SCARRING - A formulation for reducing corneal scarring and related eye conditions, is disclosed. The formulation comprises an effective amount of fibromodulin and can be administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye. | 2011-04-14 |
20110086808 | MODIFIED THERAPEUTIC AGENTS - The invention provides a modified therapeutic agent, said modified agent comprising three or more membrane binding elements with low membrane affinity covalently associated with the agent which elements are capable of interacting independently and with thermodynamic additivity, with components of cellular or artificial membranes exposed to extracellular fluids wherein at least two membrane binding elements are lipophilic elements, which may be aliphatic acyl groups, which may be selected from the list consisting of Myristoyl, Decanoyl or Hexanoyl. | 2011-04-14 |
20110086809 | Enteral Administration Of Arginine-Glutamine Dipeptide To Support Retinal, Intestinal, Or Nervous System Development - A method for supporting retinal, intestinal, and/or nervous system development in a neonate is provided. The method involves enterally administering arginine-glutamine dipeptide to a neonate. | 2011-04-14 |
20110086810 | HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE - The present invention provides hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile. | 2011-04-14 |
20110086811 | HIGH-CONCENTRATION RUTIN-CONTAINING DRINK - It is an object of the present invention to provide a packaged high-concentration rutin-containing drink suppressed the occurrence of the precipitation though it contains rutin in a high concentration. According to the invention, a packaged high-concentration rutin-containing drink includes rutin and quercetin is provided. The concentration of rutin is in a range from 70 to 1100 ppm and the ratio [(A)/(B)] by weight of (A) rutin to (B) quercetin is 3.7 to 58.0. | 2011-04-14 |
20110086812 | Transition state sturcture of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidases - Provided are methods of designing a putative inhibitor of a 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase. The methods comprise designing a chemically stable compound that resembles the charge and geometry of the 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase transition state. Also provided are methods of inhibiting 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidases using the inhibitors found by the above methods. | 2011-04-14 |
20110086813 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS - The present invention relates to a novel class of guanine nucleotide analogs which inhibit RelA and Relseq synthetic activity and which possess anti-bacterial activity. The present invention also relates to pharmaceutical compositions that include such compounds, and to methods of use of such compounds or compositions for combating bacteria and treating bacterial infections. | 2011-04-14 |
20110086814 | INHIBITING E.SAKAZAKII GROWTH - The present invention concerns the use of uronic acid saccharide for preventing growth of | 2011-04-14 |
20110086815 | NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES - The invention provides compositions comprising xanthohumol/cyclodextrin complexes that are water soluble and that have increased stability relative to xanthohumol alone. | 2011-04-14 |
20110086816 | Antimicrobial Compounds - The invention relates to cationic siloxane derivatives for use especially as fungicides and/or antiadhesives. The cationic siloxane derivatives have the formula (I), wherein R1, R2, R3, R4, R | 2011-04-14 |
20110086817 | ANTI-BACTERIAL AGENTS FROM BENZO[D]HETEROCYCLIC SCAFFOLDS FOR PREVENTION AND TREATMENT OF MULTIDRUG RESISTANT BACTERIA - Embodiments herein provide compounds and methods of making and using such compounds for prevention and treatment of multidrug resistant bacteria. In particular, embodiments are directed to anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria. | 2011-04-14 |
20110086818 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITUS - The invention features methods, compositions, and kits for selective inhibition of pain-and itch sensing neurons (nociceptors and pruriceptors) by drug molecules of small molecule weight, while minimizing effects on non-pain-sensing neurons or other types of cells. | 2011-04-14 |
20110086819 | NOVEL PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES - The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders. | 2011-04-14 |
20110086820 | ANALGESIC AGENT COMPRISING CYCLIC PHOSPHATIDIC ACID DERIVATIVE - An object of the present invention is to elucidate an analgesic effect as one of new cPA bioactivities and thus to provide a novel analgesic agent. The present invention provides an analgesic agent which comprises a cyclic phosphatidic acid derivative that is one type of phospholipid. | 2011-04-14 |
20110086821 | Tetracycline Compounds for Treatment of Cryptosporidium Parvum Related Disorders - Methods and compositions for treating | 2011-04-14 |
20110086822 | Substituted Tetracycline Compounds - The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. | 2011-04-14 |
20110086823 | DISINFECTANT - The invention relates to a disinfectant which comprises a special combination of biocidal phenols and, where appropriate, phenol derivatives and a keratolytic. The disinfectant is particularly suitable for controlling parasitic protozoa including their persistent forms. | 2011-04-14 |
20110086824 | (20S,22E)-2-Methylene-19-Nor-22-Ene-1Alpha,25-Dihydroxyvitamin D3 - This invention discloses (20S,22E)-2-methylene-19-nor-22-ene-1α,25-dihydroxyvitamin D | 2011-04-14 |
20110086825 | Therapeutic vaginal emollient - A topical composition for relief from certain menopausal, peri- and post-menopausal symptoms is disclosed, consisting of a low dosage of progesterone, testosterone and estriol in a pharmaceutically acceptable topical carrier in a weight ratio of from about 1:0.1:0.01 to about 1:0.1:0.02, respectively. In a preferred single dose, the three active ingredients are present as follows: (a) from about 20 to about 35 mg progesterone; (b) from about 2 to about 3.5 mg testosterone; and (c) from about 0.2 to about 0.7 mg estriol. A preferred carrier is cocoa butter, and a preferred single dose form is a vaginal suppository. | 2011-04-14 |
20110086826 | LIPOSOMAL CAMPTOTHECINS AND USES THEREOF - This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis. | 2011-04-14 |
20110086827 | COMBINATION MEDICAMENT - The subject matter of this application relates to the combination of ciclesonide or an epimer thereof with R,R-formoterol or a salt, or a hydrate of a salt thereof. | 2011-04-14 |
20110086828 | TREATMENT OF ALCOHOL ABUSE AND ALCOHOLISM USING MODULATORS OF NEUROSTEROID BINDING SITES ON GABAA RECEPTORS - The present invention provides methods for reducing alcohol drinking behavior in humans and treating acute alcohol poisoning through the use of neutral or negative modulating agents of the neurosteroid sites on GABA | 2011-04-14 |
20110086829 | COMPOSITIONS AND METHODS FOR TREATING OBESITY - Compositions and methods for treating obesity in a subject are described. Some embodiments provide methods for administering pharmaceutical formulations including biocompatible emulsifiers in an amount effective to treat obesity. In some embodiments, pharmaceutical formulations include a combination of two or more biocompatible emulsifiers effective to treat obesity. | 2011-04-14 |
20110086830 | METAL COMPLEXES OF N-HETEROCYCLIC CARBENES - The present invention generally relates to metal complexes of N-heterocyclic carbenes that contain one or more additional active moieties and/or groups therein. In one embodiment, the present invention relates to metal complexes of N-heterocyclic carbenes that contain an anti-fungal and/or anti-microbial moiety and/or group in combination with one or more additional active moieties and/or groups selected from fluoroquinolone compounds or derivatives thereof; steroids or derivatives thereof; anti-inflammatory compounds or derivatives thereof; anti-fungal compounds or derivatives thereof; anti-bacterial compounds or derivatives thereof; antagonist compounds or derivatives thereof; H | 2011-04-14 |
20110086831 | PROCALCITONIN FOR THE DIAGNOSIS OF BACTERIAL INFECTIONS AND GUIDANCE OF ANTIBIOTIC TREATMENT IN PATIENTS WITH ACUTE STROKE OR TRANSIENT ISCHEMIC ATTACK - The present invention relates to an in vitro method for the diagnosis and treatment guidance of a bacterial infection in patients suffering from an acute ischemic or hemorrhagic stroke, comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from said patient and the correlation of the determined level to the diagnosis of a bacterial infection in said patient. | 2011-04-14 |
20110086832 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - The present application relates to thiazolylidene containing compounds of formula (I) | 2011-04-14 |
20110086833 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY - The present invention provides nucleic acid constructs, methods for identifying and validating compounds that increase the inclusion of exon 7 of SMN2 into mRNA transcribed from the SMN2 gene, compounds and pharmaceutical compositions that increase levels of SMN protein produced from the SMN2 gene, and methods for use thereof in treating of SMA. | 2011-04-14 |
20110086834 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS - Selected compounds are effective for prophylaxis and treatment of inflammation and inflammatory disorders, such as NIK-mediated disorders. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, inflammation and the like. | 2011-04-14 |
20110086835 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors - The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer. | 2011-04-14 |
20110086836 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators - The present invention relates to substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention. | 2011-04-14 |
20110086837 | COMBINATIONS OF A PI3K INHIBITOR AND A MEK INHIBITOR - The invention relates methods of treating a patient with locally advanced or metastatic solid tumors with a combination of an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase or PI3K) and an inhibitor of mitogen activated protein kinase (MEK) described herein. | 2011-04-14 |
20110086838 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - The present invention relates to thiophene containing compounds of formula (I) | 2011-04-14 |
20110086839 | COMPOUNDS - The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders. | 2011-04-14 |
20110086840 | N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The present invention relates to compounds of Formula I: | 2011-04-14 |
20110086841 | N-9 SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The present invention relates to compounds of Formula I: | 2011-04-14 |
20110086842 | Pyrimidines as PLK inhibitors - The present invention encompasses compounds of general formula (1), | 2011-04-14 |
20110086843 | Thiazole Derivatives and Use Thereof - The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries. | 2011-04-14 |
20110086844 | Oral Solid Solution Formulation of a Poorly Water-Soluble Active Substance - An immediate release pharmaceutical formulation of a poorly water-soluble biologically active substance with enhanced bio-availability, the formulation being a homogeneous and thermostable solid solution, and the solid solution including as percentages of the total weight of the formulation:
| 2011-04-14 |
20110086845 | Compositions and Methods for Treating Neurodegenerating Diseases - This invention provides agents, compositions, pharmaceutical compositions and methods for treating or slowing the progression of a neurodegenerating disease, such as Alzheimer's disease and a demyelinating disease. | 2011-04-14 |
20110086846 | Azaindazole Compounds As CCR1 Receptor Antagonists - Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. | 2011-04-14 |
20110086847 | THIADIAZOLE MODULATORS OF BETA ADRENERGIC RECEPTOR - The present invention relates to new thiadiazole modulators of beta adrenergic receptor activity, pharmaceutical compositions thereof, and methods of use thereof. | 2011-04-14 |
20110086848 | Agrochemical Compositions Comprising Alkyl Polypropylene Glycol Polyethylene Glycol - What is described are specific agrochemical compositions comprising alkyl polypropylene glycol polyethylene glycol, processes for their preparation and the use of corresponding compositions in the agrochemical field. The present invention furthermore relates to the use of alkyl polypropylene glycol polyethylene glycol as penetrant for agrochemically active compounds and/or as spontaneity enhancer in the preparation of application liquors. | 2011-04-14 |
20110086849 | NOVEL BENZOXAZINE BENZIMIDAZOLE DERIVATIVE, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND AUSE THEREOF - The present invention relates to a novel benzoxazine benzimidazole derivative of formula (1) as an antagonist against a vanilloid receptor-1, a pharmaceutical composition comprising the same as an active ingredient, and a use thereof. The benzoxazine benzimidazole derivative of the present invention may be useful for preventing or treating a disease associated with antagonistic activity of vanilloid receptor-1: | 2011-04-14 |
20110086850 | RADIOSENSITIZATION OF TUMORS WITH INDAZOLPYRROLOTRIAZINES FOR RADIOTHERAPY - Provided herein is a method of radiosensitizing a tumor in a subject, which comprises administering to the subject a radiosensitizing amount of an indazolpyrrolotriazine of Formula I. Also provided herein is a method of treating a tumor in a subject, which comprises the steps of administering to the subject a radiosensitizing amount of an indazolpyrrolotriazine of Formula I, and a therapeutically effective fraction of radiation. | 2011-04-14 |
20110086851 | SUBSTITUTED QUINAZOLINES AND THEIR USES FOR MYEOLOPROLIFIC AND THROMBOTIC DISEASES - This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula shown below wherein the substituents have the meanings defined in claim | 2011-04-14 |
20110086852 | PHARMACEUTICAL COMPOUNDS - Compounds of formula (I), wherein R | 2011-04-14 |
20110086853 | Therapeutic Compounds - Compounds of formula I or pharmaceutically acceptable salts thereof: | 2011-04-14 |
20110086854 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS - There are provided compounds of the formula | 2011-04-14 |
20110086855 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF - The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, | 2011-04-14 |
20110086856 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 2011-04-14 |
20110086857 | N-((1R,2S,5R)-5-(TERT-BUTYLAMINO)-2-((S)-3-(7-TERT-BUTYLPYRAZOLO[1,5-A][1,- 3,5]TRIAZIN-4-YLAMINO)-2-OXOPYRROLIDIN-1-YL)CYCLOHEXYL)ACETAMIDE, A DUAL MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESSES - The present invention provides a novel antagonist: N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide: | 2011-04-14 |
20110086858 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2011-04-14 |
20110086859 | ALKYL SUBSTITUTED INDOLOQUINOXALINES - Novel substituted indoloquinoxalines of formula (I | 2011-04-14 |
20110086860 | COMPOUND - A compound represented by Formula (I) is provided: | 2011-04-14 |
20110086861 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER - Provided is a pharmaceutical composition including as an active component a compound of formula (I): | 2011-04-14 |
20110086862 | POLYMORPHS OF PARDOPRUNOX - This invention relates to a process for the preparation of 7-(4-methyl-1-piperazinyl)benzoxazol-2(3H)-one hydrochloride, a partial dopamine-D | 2011-04-14 |
20110086863 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR - The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT | 2011-04-14 |
20110086864 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF - The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis. | 2011-04-14 |
20110086865 | ANT-LIGANDS MOLECULES AND BIOLOGICAL APPLICATIONS - The invention relates to molecules ANT-ligands having a substituted nitrogeneous heterocycle A wherein —A is a substituted pyrazinone of formula I | 2011-04-14 |
20110086866 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase. | 2011-04-14 |
20110086867 | 6-(C2-6ALKYLSELENO)PURINES AND METHODS FOR TREATING NEURAL MEASLES VIRAL INFECTION THEREWITH - The present application relates to anti-viral selenopurine compounds of formula (I): wherein R | 2011-04-14 |
20110086868 | SPECIFIC INHIBITORS FOR VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS - The present application describes isoindoles and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful inhibitors of VEGFR. | 2011-04-14 |
20110086869 | METHODS FOR TREATING VIRAL DISORDERS - Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days. | 2011-04-14 |
20110086870 | Combination Therapy - The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises one of: the administration of ZD6474 in combination with 5-FU; the administration of ZD6474 in combination with CPT-11; and the administration of ZD6474 in combination with 5-FU and CPT-11; to a pharmaceutical composition comprising one of: ZD6474 and 5-FU; ZD6474 and CPT-11; and ZD6474 and 5-FU and CPT-11; to a combination product comprising one of: ZD6474 and 5-FU; ZD6474 and CPT-11; and ZD6474 and 5-FU and CPT-11, for use in a method of treatment of a human or animal body by therapy; to a kit comprising one of: ZD6474 and 5-FU; ZD6474 and CPT-11; and ZD6474 and 5-FU and CPT-11; to the use of one of: ZD6474 and 5-FU; ZD6474 and CPT-11; and ZD6474 and 5-FU and CPT-11, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation. | 2011-04-14 |
20110086871 | RIFAXIMIN COMPOSITIONS AND METHOD OF USE - Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin γ are described, along with the production of medicinal preparations containing rifaximin for oral and topical use. | 2011-04-14 |
20110086872 | Berberine as a selective lung cancer agent and other compositions and methods - Berberine or its salts or derivatives are identified as the active compound for selectively inhibiting lung cancer, potentially without toxic side effects. Berberine is preferably obtained by synthesis or partial synthesis, or is obtained from natural sources, such as | 2011-04-14 |
20110086875 | Powdered Medicament for Nasal Delivery of Ascorbic Acid for Reducing Apomorphine Induced Toxicity to Ciliated Tissue - Use of ascorbic acid in the manufacture of a powdered medicament for nasal delivery, said medicament comprising an active agent such as apomorphine that exhibits toxicity to ciliated tissue, for ameliorating said toxicity. | 2011-04-14 |
20110086876 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION - Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles. | 2011-04-14 |
20110086877 | Small Molecule Inhibitors of Botulinum Neurotoxins - Disclosed herein are methods of inhibiting the activity of Botulinum neurotoxin A metalloprotease with the compounds disclosed herein. Also disclosed are methods of treating, inhibiting or preventing intoxication caused by bacteria of at least one bacterial strain in a subject, and pharmaceutical and cosmetic compositions comprising the compounds disclosed herein. | 2011-04-14 |
20110086878 | Treatments for Neuropathy - Small fiber neuropathy is treated or prevented by topically administering to a subject in need thereof topically active quinoline compounds or pharmaceutically acceptable salts thereof under conditions effective to treat or prevent neuropathy in the subject. Glial cell-derived neurotrophic factor (GDNF) receptors are modulated with the subject active quinoline compounds, which may be formulated in topical lotions. | 2011-04-14 |
20110086879 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS - The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. | 2011-04-14 |
20110086880 | NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel alkyl substituted piperidine derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 2011-04-14 |
20110086881 | CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND - The invention relates to crystalline free base forms of biphenyl-2-ylcarbamic acid 1-[2-(4-{[(R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]methyl}-2,5-dimethylphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof. This invention also relates to pharmaceutical compositions containing or prepared from such crystalline forms; processes and intermediates useful for preparing such crystalline forms; and methods of using such crystalline forms to, for example, treat a pulmonary disorder. | 2011-04-14 |
20110086882 | PYRAZOLOTHIAZOLE COMPOUND - A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism | 2011-04-14 |
20110086883 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) - The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor. | 2011-04-14 |
20110086884 | BARIUM SALT OF BENZIMIDAZOLE DERIVATIVE - The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared. | 2011-04-14 |
20110086885 | Indole-2-carboxylic acid amides - Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants. | 2011-04-14 |
20110086886 | INSECTICIDAL ISOXAZOLINES -
Novel isoxazolines of the formula (I)
| 2011-04-14 |
20110086887 | Oil-Based Suspension Concentrates - The present invention relates to new, oil-based suspension concentrates of active agrochemicals, to a process for producing these formulations and to their use for applying the active substances comprised. | 2011-04-14 |
20110086888 | Fungicidally Active Compound Combinations - The invention relates to novel fungicidallly active compound combinations of 2′-cyano-3,4-dichloroisothiazole-5-carboxanilide of the formula | 2011-04-14 |
20110086889 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS - The invention relates to tetrazole compounds of formula (I) wherein X, Y, Z, R | 2011-04-14 |
20110086890 | LIQUID PEST CONTROL FORMULATION - The present invention relates to a liquid pest control system that includes a synthetic pyrethroid as a pest control active ingredient and an agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol nicotinate and tocopherol succinate, and combinations thereof, to reduce or eliminate paraesthesia of the synthetic pyrethroid. The system releases the synthetic pyrethroid efficiently and uniformly. The pest control system is less irritating to the animal's skin as compared to prior art systems, particularly to the small breeds of dogs. The system is useful for making liquid spot-on treatments, sprays and the like. | 2011-04-14 |
20110086891 | Solid Forms of 2-(2,4-Difluorophenyl)-6-(1-(2,6-Difluorophenyl)Ureido)Nicotinamide) - This invention relates to solid forms of 2-(2,4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide and pharmaceutical compositions thereof, and methods and uses therewith. | 2011-04-14 |
20110086892 | Pre-Mixed, Ready-To-Use Pharmaceutical Compositions - Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions. | 2011-04-14 |
20110086893 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS - Compounds formula (IA) or (IB), wherein W represents HO(C═O)—, HONH(C═O)— or H(C═O)N(OH)—; X represents —O— or —S—; and R | 2011-04-14 |
20110086894 | BIOMARKERS FOR THE DIAGNOSIS OF ALS - Methods for determining the onset of ALS in a subject are provided. One method includes analyzing a sample obtained from the subject for the presence or amount of one or more biomarkers indicative of ALS. In a preferred embodiment, the biomarkers are one or more of the following: C-reactive protein (CRP), cystatin c, plasminogen, complement C3, CysGly-transthyretin, and phosphorylated neurofilament heavy chain (pNFH). The sample is typically cerebral spinal fluid (CSF). The levels or concentrations of the biomarkers can be used to determine the onset of ALS, monitor the progression of ALS, or monitor the progression of a treatment for ALS. | 2011-04-14 |
20110086895 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS - A method of inhibiting glycolysis in a subject by administering a pharmaceutical composition including a thiazolidinedione derivative to the subject is described. The thiazolidinedione derivatives are effective energy restriction mimetic agents, and can therefore be used to treat or prevent cancer in a subject, treat metabolic disorder, or increase the longevity of a subject. Various thiazolidinedione derivatives are also suitable for activating adenosine phosphate-activated protein kinase or inhibiting IL-6 expression. | 2011-04-14 |
20110086896 | Crystalline and Stable Form of Andolast - Described is a new crystalline Form A of Andolast disodium salt, triclinic, displaying a thermal event at 98-112° C. and melting with decomposition at about 400° C. (DSC). Andolast disodium Form A is a not hygroscopic solid, surprisingly stable to several humidity conditions in a temperature range acceptable for ordinary storage conditions. In addition its stability allows both chemical manufacturing and pharmaceutical manufacturing process consistency and reproducibility under conditions more viable and less expensive when compared to those used for highly hygroscopic solids. | 2011-04-14 |
20110086897 | (E)-N-(2-Amino-phenyl)-3--acrylamide salts - A salt of (E)-N-{2-amino-phenyl)-3-{1-[4-(1-methyl-1H-pyrazol-4-yl)-beπzenesulfonyl]-1H-pyrrol-3-yl)-acrylamide selected from the group consisting of the hydrobromide, methansulfonate, hemi ethane-1,2-disulfonate, benzenesulfonate, toiuenesulfonate and 2-naphthalenesulfonate. | 2011-04-14 |
20110086898 | PYRAZOLOOXAZOLE COMPOUND - A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism. | 2011-04-14 |
20110086899 | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION - This invention is directed to pharmaceutical compositions for oral administration to a mammal, wherein the pharmaceutical compositions comprise a spiro-oxindole compound, as a single stereoisomer or as a mixture thereof, or a pharmaceutically acceptable salt thereof. These pharmaceutical compositions are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. | 2011-04-14 |